Who are CB-03-01's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dutasteride Capsules, minoxidil + finasteride, Dutasteride/Tamsulosin, Pre-randomization Dutasteride, Saw palmetto berry extract, Combodart®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cb-03-01.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

CB-03-01 — Competitive Intelligence Brief

CB-03-01 (CB-03-01) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: 5-alpha reductase inhibitor. Area: Dermatology.

phase 2 5-alpha reductase inhibitor 5-alpha reductase Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

CB-03-01 (CB-03-01) — Intrepid Therapeutics, Inc.. CB-03-01 is a selective androgen receptor modulator (SARM) that inhibits 5-alpha reductase to reduce DHT-driven androgenetic alopecia.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CB-03-01 TARGET	CB-03-01	Intrepid Therapeutics, Inc.	phase 2	5-alpha reductase inhibitor	5-alpha reductase
Dutasteride Capsules	Dutasteride Capsules	UConn Health	marketed	5-alpha reductase inhibitor	5-alpha reductase (type 1 and type 2)
minoxidil + finasteride	minoxidil + finasteride	Beijing Dayspring Pharmaceutical Technology Co., Ltd	marketed	Combination antialopecia agent	Potassium channels (minoxidil); 5-alpha reductase type II (finasteride)
Dutasteride/Tamsulosin	Dutasteride/Tamsulosin	GlaxoSmithKline	marketed	5-alpha reductase inhibitor / alpha-1 adrenergic antagonist combination	5-alpha reductase (type I and II) / alpha-1A adrenergic receptor
Pre-randomization Dutasteride	Pre-randomization Dutasteride	Siami, Paul F., M.D.	marketed	5-alpha reductase inhibitor	5-alpha reductase (type 1 and type 2)
Saw palmetto berry extract	Saw palmetto berry extract	A. Vogel AG	marketed	Herbal extract; 5-alpha reductase inhibitor	5-alpha reductase; androgen receptor (indirect)
Combodart®	Combodart®	Ache Laboratorios Farmaceuticos S.A.	phase 3	Combination therapy: 5-alpha reductase inhibitor + alpha-1A adrenergic antagonist	5-alpha reductase (types I and II); alpha-1A adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (5-alpha reductase inhibitor class)

Intrepid Therapeutics, Inc. · 1 drug in this class
Siami, Paul F., M.D. · 1 drug in this class
UConn Health · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CB-03-01 — Competitive Intelligence Brief. https://druglandscape.com/ci/cb-03-01. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab